Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H1 2017

  • ID: 4318716
  • Drug Pipelines
  • 39 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CrystalGenomics Inc
  • iNtRON Biotechnology Inc
  • Wockhardt Ltd
  • MORE
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H1 2017, provides an overview of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline landscape.

Vancomycin resistant staphylococcus infection is a condition caused by bacteria (germs). This infection occurs when bacteria, called Staphylococcus aureus or Staph, becomes resistant (not killed) to the antibiotic medicine vancomycin. Risk factors include taking strong antibiotics the wrong way may cause the bacteria to develop resistance to the antibiotics, weak immune system and staying in the hospital too long. Symptoms include fever, chills, cough, chest pain, trouble breathing, and a fast heartbeat.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CrystalGenomics Inc
  • iNtRON Biotechnology Inc
  • Wockhardt Ltd
  • MORE
  1. Introduction
  2. Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Overview
  3. Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Companies Involved in Therapeutics Development
  15. CrystalGenomics Inc
  16. Debiopharm International SA
  17. iNtRON Biotechnology Inc
  18. Wockhardt Ltd
  19. Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drug Profiles
  20. CG-400549 - Drug Profile
  21. Product Description
  22. Mechanism Of Action
  23. R&D Progress
  24. Debio-1450 - Drug Profile
  25. Product Description
  26. Mechanism Of Action
  27. R&D Progress
  28. Epidermicin NI-01 - Drug Profile
  29. Product Description
  30. Mechanism Of Action
  31. R&D Progress
  32. Small Molecule to Inhibit PBP2 for Gram-Positive Bacterial Infections - Drug Profile
  33. Product Description
  34. Mechanism Of Action
  35. R&D Progress
  36. Small Molecule to Inhibit PBP2a for Gram-Positive Bacterial Infections - Drug Profile
  37. Product Description
  38. Mechanism Of Action
  39. R&D Progress
  40. Small Molecule to Target Bacterial Cell Wall for MRSA and VRSA Infections - Drug Profile
  41. Product Description
  42. Mechanism Of Action
  43. R&D Progress
  44. Small Molecules to Activate Perforin-2 Synthesis for Bacterial Infections - Drug Profile
  45. Product Description
  46. Mechanism Of Action
  47. R&D Progress
  48. Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile
  49. Product Description
  50. Mechanism Of Action
  51. R&D Progress
  52. Small Molecules to Target Bacterial Cell Wall for Vancomycin-Resistant Enterococcus faecium and Staphylococcus aureus Infections - Drug Profile
  53. Product Description
  54. Mechanism Of Action
  55. R&D Progress
  56. tonabacase - Drug Profile
  57. Product Description
  58. Mechanism Of Action
  59. R&D Progress
  60. WCK-4086 - Drug Profile
  61. Product Description
  62. Mechanism Of Action
  63. R&D Progress
  64. Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects
  65. Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products
  66. Appendix
  67. Methodology
  68. Coverage
  69. Secondary Research
  70. Primary Research
  71. Expert Panel Validation
  72. Contact Us
  73. Disclaimer
List of Tables
  1. Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Products under Development by Companies, H1
  5. Products under Development by Universities/Institutes, H1
  6. Number of Products by Stage and Target, H1
  7. Number of Products by Stage and Mechanism of Action, H1
  8. Number of Products by Stage and Route of Administration, H1
  9. Number of Products by Stage and Molecule Type, H1
  10. Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by CrystalGenomics Inc, H1
  11. Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Debiopharm International SA, H1
  12. Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by iNtRON Biotechnology Inc, H1
  13. Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Wockhardt Ltd, H1
  14. Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects, H1
  15. Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products, H1
List of Figures
  1. Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Number of Products by Targets, H1
  5. Number of Products by Stage and Targets, H1
  6. Number of Products by Mechanism of Actions, H1
  7. Number of Products by Stage and Mechanism of Actions, H1
  8. Number of Products by Routes of Administration, H1
  9. Number of Products by Stage and Routes of Administration, H1
  10. Number of Products by Molecule Types, H1
  11. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • CrystalGenomics Inc
  • Debiopharm International SA
  • iNtRON Biotechnology Inc
  • Wockhardt Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll